On November 4, 2019 MAX BioPharma, Inc. (www.maxbiopharma.com) reported that published two articles describing its anti-tumorigenic oxysterol lead compounds in the peer-reviewed journal, Cells (Press release, MAX BioPharma, NOV 4, 2019, View Source [SID1234550237]). Oxy186 (View Source) and Oxy210 (View Source) are derived from the Company’s Oxysterol Therapeutics platform of proprietary oxysterols. MAX BioPharma is currently optimizing the compounds for oral dosing and performing pre-clinical studies required by the FDA for clinical development and commercialization.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MAX BioPharma’s anti-tumorigenic oxysterol, Oxy186, inhibits the Hedgehog signaling pathway, which is dysregulated and activated in many human tumors including pancreatic and lung cancers. Oxy210, an analogue of Oxy186, inhibits Hedgehog signaling as well as transforming growth factor (TGF)beta signaling. Oxy210 and Oxy186 have unique mechanisms of action compared to other Hedgehog and TGFbeta signaling inhibitors that are commercially available or under clinical development. MAX BioPharma is focusing its efforts to develop these compounds for lung and pancreatic cancers, which still have huge unmet medical needs. Oxy210 and Oxy186 have favorable pharmacokinetic and safety profiles, are scalable, and were found to inhibit tumor cell growth, invasive activity, and epithelial-mesenchymal transition, a hallmark of cancer metastasis. In addition, Oxy210 was found to inhibit development of chemoresistance by tumor cells and to enhance the cytotoxic effects of carboplatin on lung cancer cells in vitro.
MAX BioPharma has collaborated with Dr. Ying Zhang of the National Cancer Institute (NCI) under a Materials-Cooperative Research and Development Agreement (M-CRADA) and with academic investigators. These collaborations are evaluating the potential of the oxysterols to be potent, orally bioavailable, and safe therapies for cancer. "Given the important role of Hedgehog signaling in acute myeloid leukemia (AML) and the recent FDA approval of a Hedgehog pathway inhibitor, DaurismoTM (glasdegib) by Pfizer, for the treatment of AML, we are excited to begin examining the potential of oxysterols for targeting AML" explains Dr. William Matsui, co-founder of MAX BioPharma and Professor of Oncology and Deputy Director of LIVESTRONG Cancer Institutes at the University of Texas in Austin. MAX BioPharma is seeking strategic partnerships with biotechnology and pharmaceutical companies that have the expertise and resources to further the development of oxysterols as a cancer therapeutic towards FDA approval and commercialization. In addition, MAX BioPharma is in the process of raising a series A financing round to support the advancement of its therapeutic development programs. "We are extremely excited about the progress of our oncology program and we believe that our findings will be groundbreaking in finding more effective cures for cancer," says Dr. Farhad Parhami, President & CEO of MAX BioPharma.